Details for Patent: 4,877,805
Summary for Patent: 4,877,805
| Title: | Methods for treatment of sundamaged human skin with retinoids | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Various effects of photoaging or sundamage of skin including impairment of differentiation of epidermal epithelial cells and loss of collagen fibers, abnormal changes in elastic fibers and deterioration of small blood vessels in the dermis of the skin are retarded by applying topically to the epidermis in a maintenance therapy program effective amounts of retinoids including retinoid derivatives and stereoisomers thereof such that epithelial growths are substantially reduced and prevented and the skin substantially regains and maintains its firmness, turgor and elasticity. Moreover, with persistent treatment dermal blood cells and vessels increase and the epidermis and dermis thicken, resulting in improved ability of the skin to sense, resist and recover from irritation or injury. Further, hyperpigmentation, lines and wrinkles due to aging are reduced and prevented. The treatment is particularly useful for human facial skin and preferably applied in amounts insufficient to cause excessive irritation. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Albert M. Kligman | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Individual | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US07/205,057 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Drug Patent 4,877,805: Claim Scope, Expiration, and Retinoid Patent LandscapeU.S. Patent No. 4,877,805 covered topical maintenance treatment of photoaged human skin with retinoids. Its central claim required four elements: topical application, a retinoid-containing dermatologically acceptable composition, a maintenance-therapy program, and a dose low enough to avoid excessive irritation while improving or maintaining firmness, turgor, and elasticity. The patent issued on October 31, 1989, and its ordinary 17-year term expired on October 31, 2006. The patent therefore has no current blocking force in the United States. The patent was commercially important because it claimed a therapeutic use of retinoids for sun-damaged skin rather than merely claiming a particular molecule or formulation. Its claims reached tretinoin-related compounds, 13-cis-retinoic acid, retinol, synthetic retinoids, creams, ointments, and emollient vehicles. The claim language was broad, but several limitations created material validity and infringement issues, particularly the functional treatment result, the maintenance-therapy requirement, and the requirement to avoid excessive irritation. What does U.S. Patent 4,877,805 cover?U.S. Patent 4,877,805 covers a method of treating photoaged skin by repeatedly applying a retinoid composition at a tolerable dose. The patent is directed to biological changes associated with chronic ultraviolet exposure, including:
The independent claim does not require a particular concentration, application frequency, brand, dosage form, or named retinoid. Instead, it uses functional and operational limitations.
The claim is a treatment-method claim. It does not claim retinoic acid as a chemical compound, nor does it claim every cosmetic use of a retinoid. How do the individual claims differ?Claim 1: Broad method claimClaim 1 is the principal scope-defining claim. A potentially infringing practice would have needed to satisfy all of the following:
The claim does not expressly require facial skin, a cream, retinol, tretinoin, or a particular concentration. Its main limitation is that it combines structural features with functional results. A product used only for acne, keratinization disorders, or another non-photoaging indication would not automatically fall within the claim. The method also requires treatment of sun-damaged skin, not simply normal skin or skin with transient dryness. Claims 2 and 3: Retinoic-acid classesClaim 2 narrows claim 1 to retinoic acids, retinoic-acid derivatives, and stereoisomers. Claim 3 further narrows the class to 13-cis-retinoic acid, derivatives, and stereoisomers. 13-cis-retinoic acid is isotretinoin. The claim language would not automatically cover all retinoids because a product would need to fall within the specified retinoic-acid category. Claim 4: Named synthetic retinoidsClaim 4 identifies three specific retinoid structures, including compounds related to:
These compounds appear to be experimental or investigational retinoids rather than the principal commercial ingredients used in modern consumer dermatology. Claim 4 would have been useful against use of the expressly listed compounds, but it would not automatically cover unrelated retinoid structures. Claim 5: Extended Markush-style listClaim 5 identifies a larger list of named retinoids, including:
This claim is narrower than claim 1 because it requires use of one of the listed compounds. The list likely reflects the patent’s effort to cover known and experimental retinoid agonists, not only commercial retinoids. Claims 6 through 8: Facial skinClaims 6, 7, and 8 narrow the method to human facial skin. These claims would have been particularly relevant to anti-wrinkle creams and facial dermatology products. Claims 9 and 10: Vehicle limitationsClaim 9 requires a cream or ointment vehicle. Claim 10 requires an emollient vehicle. These claims narrow the broader vehicle language in claim 1 but still leave substantial formulation flexibility. A cream, ointment, lotion, emulsion, gel, or emollient system could potentially satisfy claim 1 depending on the facts. Claims 9 and 10 would require the more specific vehicle characteristics. Claim 11: RetinolClaim 11 expressly covers retinol. This is commercially significant because retinol is widely used in nonprescription cosmetic products, while tretinoin is generally supplied as a prescription drug in the United States. Claim 11 still depends on claim 1. Retinol use alone would not have been enough. The product and treatment would also have needed to satisfy the photoaged-skin, maintenance-therapy, dosage, vehicle, and therapeutic-result limitations. When did U.S. Patent 4,877,805 lose exclusivity?The patent issued on October 31, 1989. Under the pre-Uruguay Round patent-term rule applicable to this patent, the ordinary term was 17 years from issue. The resulting expiration date was October 31, 2006, absent an earlier terminal disclaimer or unusual term adjustment.
The patent’s expiration means that a company does not need a license under U.S. Patent 4,877,805 to market a retinoid product or practice the claimed photoaging treatment method in the United States. The patent’s expiration does not eliminate later patents directed to specific formulations, delivery systems, combinations, manufacturing processes, packaging, or separate clinical uses. What is the Orange Book status of U.S. Patent 4,877,805?U.S. Patent 4,877,805 is not a current Orange Book exclusivity barrier. The Orange Book lists patents submitted for approved drug products and does not operate as a general register of every patent covering a therapeutic concept or ingredient. The patent was directed to a broad method of treating photoaged skin. It was not a compound patent for tretinoin, isotretinoin, or retinol. It also was not limited to an FDA-approved product, strength, or dosage form. For FDA-approved tretinoin products, Orange Book analysis must be conducted at the product level. Relevant products have included tretinoin creams, gels, and lotions for acne, as well as prescription products marketed for facial fine wrinkles. A patent listed against one approved product would not necessarily cover all tretinoin products or all retinol cosmetics. The distinction is material:
FDA approval of a retinoid product does not revive an expired method patent. Conversely, the absence of an Orange Book listing does not prove that no later patent exists. How strong was the patent estate?The patent estate was conceptually broad but legally vulnerable in several respects. StrengthsThe patent had meaningful breadth because claim 1 did not depend on:
The claim also addressed the treatment program and intended biological outcome, which made it relevant to prescription and cosmetic anti-aging products. The express inclusion of retinol in claim 11 expanded the commercial reach beyond prescription retinoic acid products. Claims 6 through 10 addressed commercially common product configurations such as facial creams and emollient vehicles. WeaknessesThe patent’s central limitations created potential enforcement problems. First, “maintenance therapy” requires more than a single application or short course. A defendant could argue that an accused product was intended for occasional cosmetic use rather than a defined maintenance program. Second, “insufficient to cause excessive irritation” is relative and fact-dependent. The claim does not provide a single objective irritation threshold. Evidence would likely have been needed concerning dose, frequency, patient tolerability, labeling, clinical studies, and actual use. Third, “substantially regains and maintains its firmness, turgor and elasticity” is a functional result. A method claim may be difficult to prove where the product label does not make the claimed therapeutic representation and clinical evidence is mixed. Fourth, “sun-damaged skin” requires a condition-specific factual showing. Use on ordinary skin, acne, hyperpigmentation, or general cosmetic aging would not necessarily satisfy the limitation. Finally, the patent issued before modern pharmaceutical patent litigation routinely separated compound, formulation, method-of-use, and manufacturing claims. Later patent owners generally pursued narrower claims with more measurable parameters. What formulations were protected by the patent?The patent covered formulations only through the method claims. It did not claim a specific composition by concentration, excipient, particle size, release profile, or manufacturing process. Potentially relevant vehicles included:
The formulation had to contain an effective amount of retinoid and deliver a dose that avoided excessive irritation. The patent therefore had method-of-use coverage over a wide range of formulations, but it did not create a durable formulation patent estate. Later formulation patents in the retinoid field have generally focused on:
Those later rights must be assessed separately by product and jurisdiction. Are there Paragraph IV challenges to this patent?No current Paragraph IV challenge can have practical effect against U.S. Patent 4,877,805 because the patent expired in 2006. A Paragraph IV certification applies when an Abbreviated New Drug Application applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed. An expired patent cannot ordinarily support a future 30-month stay or block approval on its own. Paragraph IV disputes involving generic tretinoin or other retinoids would instead concern later Orange Book-listed patents, if any, covering a particular approved product or formulation. They would not revive or extend the term of U.S. Patent 4,877,805. What litigation and settlement agreements affected the patent?There is no current litigation exposure under U.S. Patent 4,877,805 because its term has ended. The patent’s expiration also removes any continuing settlement leverage based solely on this patent. The available patent record identifies the patent and its claims but does not establish a current settlement agreement, ongoing infringement action, or enforceable license obligation tied to this patent. A commercial agreement may have existed historically, but it would not be inferable from the issued patent alone. Any diligence review should separate:
Does the patent create biosimilar risk?No. Retinoids are chemically synthesized small molecules, not biological products. Biosimilar approval under the Public Health Service Act is therefore not the relevant pathway. The competitive pathways are:
The patent did not create biologic exclusivity, reference-product exclusivity, or biosimilar market protection. How does the patent compare with later retinoid patent strategies?
The original patent’s broad method claim could have created early freedom-to-operate concerns for anti-photoaging products. Its expiration shifted commercial risk toward later patents and regulatory exclusivity tied to individual products. What generic launch risks exist today?For the expired patent itself, generic launch risk is zero in the United States. A generic or branded company can practice the claimed method without infringing an enforceable U.S. patent. Remaining risks may arise from:
A company launching a retinoid product should therefore conduct a product-specific freedom-to-operate review rather than treating the expired patent as the relevant asset. What geographic coverage did the patent have?U.S. Patent 4,877,805 provided rights only in the United States. Patent protection in Europe, Japan, Canada, or other markets would have required separate national or regional patents. Foreign patent terms may have differed because of:
The U.S. expiration date cannot be applied automatically to foreign counterparts. What is the commercial significance of the patent’s expiration?The patent’s expiration removed the principal historical method-of-use barrier to topical retinoid treatment of photoaged skin in the United States. It also eliminated the ability to demand royalties or injunctions based solely on the claimed use of retinoids, including retinol, in facial creams or emollient vehicles. Commercial value now lies in later rights and regulatory assets, including:
The patent’s historical contribution was broad therapeutic-use coverage. Its present economic value as an enforceable patent is zero. Key Takeaways
FAQsCan a company market retinol anti-aging products without a license to U.S. Patent 4,877,805?Yes. The patent expired on October 31, 2006. A license is not required to practice its expired U.S. claims. Did U.S. Patent 4,877,805 cover tretinoin itself?No. It covered a treatment method using retinoids. It was not a composition-of-matter patent on tretinoin. Did the patent cover cosmetic claims for reducing wrinkles?Potentially, if the marketed method satisfied the claim limitations, including sun-damaged human skin, maintenance therapy, tolerable dosing, and the claimed improvement in firmness, turgor, and elasticity. The patent is now expired. Can an expired method patent block FDA approval of a generic retinoid?No. An expired patent cannot independently create a current Orange Book stay or prevent approval. Later listed patents may present separate issues. Does the patent protect retinoid manufacturing methods?No. The claims provided are treatment-method claims. They do not claim synthesis, purification, polymorphs, stability processes, or commercial manufacturing methods. References
More… ↓ |
Drugs Protected by US Patent 4,877,805
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 4,877,805
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 5289686 | ⤷ Start Trial | |||
| Australia | 598454 | ⤷ Start Trial | |||
| Australia | 599135 | ⤷ Start Trial | |||
| Australia | 7804687 | ⤷ Start Trial | |||
| Canada | 1303996 | ⤷ Start Trial | |||
| Canada | 1324962 | ⤷ Start Trial | |||
| Germany | 3440831 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
